-
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Previously Published on Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Lineage Cell Therapeutics Inc. (AMEX: LCTX) recently provided an update on its lead program OpRegen®, a cell replacement therapy for dry age-related macular degeneration (AMD) with geographic atrophy (GA). Lineage is pioneering a new branch of medicine, which is manufacturing differentiated cell types and transplanting those cells into the body, to restore or improve function which has been lost due to injury or disease. The data from an ongoing Phase 1/2a clinical study continued to demonstrate that a single administration of OpRegen, an investigational cell therapy consisting of…
You May Also Like
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
Delphi360™ to Officially Launch, Improve the Work Environment and Change Indoor Air Quality Forever
-
Age-Related Macular Degeneration: What is Dry AMD, and How is Lineage Cell Therapeutics Changing the Game?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Age-related macular degeneration (AMD) is a disease originating in the retina, which may worsen over time, according to WebMD. It’s said to be the leading cause of severe, permanent vision loss in people older than 60. When the macula — the small central portion of the retina — wears down, the light-sensing nerve tissue at the back of the eye begins to deteriorate. While it doesn’t always cause complete blindness, severe vision problems such as loss of central vision may occur. As the condition worsens,…
